Methylprednisolone and the adult respiratory distress syndrome.
Total hip replacement was carried out on 22 patients under general anaesthesia. Of these, 10 were pretreated with methylprednisolone (30 mg/kg); 1 of these developed the adult respiratory distress syndrome (ARDS) and had high levels of thromboxane B2 (TXB2) 5 minutes after fixation of the femoral prosthesis and at the end of the operation. The other 12 patients served as controls; 5 of them developed ARDS and had statistically significant higher TXB2 levels than the other 7 control patients who remained well. All patients who did not develop ARDS had low TXB2 levels. TXB2 and beta-thromboglobulin levels followed the same trend and there was good correlation (r=0,6806; P less than 0,01) at the end of the operation in the control group patients who developed ARDS. There was no statistical difference in 6-keto-PGF1 alpha levels between the patients who developed ARDS and those in the control group who remained well. Steroids reduce arachidonic acid metabolism by inhibiting the release of substrate for cyclo-oxygenase and lipoxygenase activity. Patients prone to ARDS thus benefit from methylprednisolone administration.
D000368:Aged; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000378:metabolism; D011464:Epoprostenol / Q000097:blood; D006621:Hip Joint / Q000601:surgery*; D006622:Hip Prosthesis; D006801:Humans; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D011183:Postoperative Complications; D012128:Respiratory Distress Syndrome / Q000097:blood / Q000517:prevention & control*; D013928:Thromboxane A2 / Q000097:blood; D013929:Thromboxane B2 / Q000097:blood; D013997:Time Factors; D001620:beta-Thromboglobulin / Q000032:analysis
D001095:Arachidonic Acids; D001620:beta-Thromboglobulin; D016718:Arachidonic Acid; D013929:Thromboxane B2; D013928:Thromboxane A2; D011464:Epoprostenol; D008775:Methylprednisolone